Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

In connection with the leadership transition, Lars Rebien Sørensen, Chair of the Novo Nordisk Foundation and former CEO of NVO, will initially join the company’s board as an observer ...

Jørgensen will stay on as CEO temporarily for an undetermined period of time “to support a smooth transition” as the company looks for his replacement. Novo Nordisk’s value more than ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk (NVO) stock falls as the company CEO Lars Fruergaard Jørgensen steps down after 8 years of leadership marked by surging profits & sales. Read more here.

Lars Fruergaard Jørgensen has agreed to continue as CEO for a period to support a smooth transition to new leadership. Furthermore, the Novo Nordisk Board has agreed with the Novo Nordisk ...

On May 19, BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the ...

As part of the transition period, Lars Rebien Sørensen ... with operating profit ranging from approximately $5.4 to $6.3 billion. 2 “Serving as Novo Nordisk’s CEO for the past eight years has been a ...